ezbaccarattable| Hengrui Pharmaceutical (600276.SH): Subsidiary SHR-A1921 for injection is expected to be included in the public list of breakthrough treatment varieties

Zhitong Finance APP Newsezbaccarattable, Hengrui Pharmaceutical (600276ezbaccarattable.SH) Announcementezbaccarattable, SHR-A1921 for injection from the company's subsidiary Suzhou Shengdiya Biomedical Co., Ltd. is planned to be included in the publicity list of breakthrough treatment varieties by the Center for Drug Evaluation of the State Food and Drug Administration, with a publicity period of 7 days. Proposed indication (or functional indications) of this drug: It is used to treat platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.